CARAGEA c. ROUMANIE
14157/20 - Communicated Case
14157/20 - Communicated Case
13816/22 - Communicated Case
28183/22 - Communicated Case
56889/17 - Communicated Case
47070/20 - Admissibility Decision
38059/12 - Committee Judgment
41418/23 - Communicated Case
41249/23 - Communicated Case
175/24 - Communicated Case
21714/22;25102/22;25367/22 - Admissibility Decision
22976/21 -
57272/19 -
54373/19 -
7011/19 -
21714/22;25102/22;25367/22 - Legal Summary
21714/22;25102/22;25367/22 - Legal Summary
18887/11 - Admissibility Decision
39627/16 -
21951/17 -
15972/20 -
19746/23 -
1400/22;18047/22;18056/22 -
15646/22;18440/22;19100/22;30054/22;31537/22;51056/22 -
42565/16 -
Targeted cell therapy helps some patients with intractable lymphoma, but those who relapse have few options. Stanford Medicine researchers found that modifying the molecular target significantly improved outcomes.